Current standard of care for DMO in the UK is to reduce macular oedema using intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents if central retinal thickness (CRT) is ≥400 μm [5, 6]. This evidence concerns the gene VEGFA and macular retinal edema.